tiprankstipranks
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
PremiumPress ReleasesCentessa Pharmaceuticals to Participate in Upcoming Investor Conferences
2M ago
Centessa’s Drug Development Hurdles: FDA Fast Track No Guarantee for Hemophilia B Treatment Approval
PremiumCompany Announcements
Centessa’s Drug Development Hurdles: FDA Fast Track No Guarantee for Hemophilia B Treatment Approval
2M ago
Centessa reports Q1 EPS (38c), consensus (42c)
PremiumThe Fly
Centessa reports Q1 EPS (38c), consensus (42c)
2M ago
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
PremiumPress ReleasesCentessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
3M ago
Centessa announces $100M American Depositary Shares offering
PremiumThe Fly
Centessa announces $100M American Depositary Shares offering
3M ago
Centessa Pharmaceuticals Advances Narcolepsy Drug Trials
PremiumCompany Announcements
Centessa Pharmaceuticals Advances Narcolepsy Drug Trials
3M ago
CNTA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsCNTA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
4M ago
Centessa Pharmaceuticals Unveils Clinical Data Online
PremiumCompany Announcements
Centessa Pharmaceuticals Unveils Clinical Data Online
5M ago
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
PremiumPress Releases
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100